デフォルト表紙
市場調査レポート
商品コード
1439653

経鼻ドラッグデリバリーの世界市場:洞察、競合情勢、市場予測:2030年

Intranasal Drug Delivery - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
経鼻ドラッグデリバリーの世界市場:洞察、競合情勢、市場予測:2030年
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の経鼻ドラッグデリバリーの市場規模は、2023年に460億米ドルとなりました。同市場は、2024年から2030年までの予測期間中に6.29%のCAGRで拡大し、2030年には663億3,000万米ドルに達すると予測されています。経鼻ドラッグデリバリー市場は、鼻炎や副鼻腔炎など様々な呼吸器疾患の負担が世界的に増加していること、投与が容易で有効性が高いことから経鼻ドラッグデリバリーに対する患者の嗜好が高まっていること、様々な症状における鼻腔内薬剤の適用拡大、製品承認や上市の増加などにより、成長が見込まれています。

世界中で呼吸器疾患の負担が増加しているため、経鼻ドラッグデリバリー市場は大幅に増加しています。

鼻副鼻腔炎は、鼻腔と副鼻腔の炎症に関連する一般的な疾患です。世界アレルギー機関(World Allergy Organization)の報告書(2022年)によると、慢性鼻副鼻腔炎(CRS)の世界の有病率は、中国で約8%、韓国で8.4%、欧州で11%、米国で12%となっています。

また、国際鼻科学会(International Rhinologic Society 2020)の報告によると、通常ウイルス性感冒の結果として起こる急性鼻副鼻腔炎の1年間の有病率は6~15%であるのに対し、CRSは一般人口の5~12%と推定されています。

また、大人と子供のアレルギーを支援する英国の医療慈善団体Allergy UKによると、2020年には英国で約49%の人がアレルギー性鼻炎に悩まされていると報告されています。

当レポートでは、世界の経鼻ドラッグデリバリー市場について調査し、市場の概要とともに、剤形別、容器別、システム別、治療用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 経鼻ドラッグデリバリー市場レポートのイントロダクション

第2章 経鼻ドラッグデリバリー市場のエグゼクティブサマリー

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 経鼻ドラッグデリバリー市場の主な要因分析

  • 経鼻ドラッグデリバリー市場の促進要因
  • 経鼻ドラッグデリバリー市場の抑制要因と課題
  • 経鼻ドラッグデリバリー市場の機会

第5章 経鼻ドラッグデリバリー市場におけるポーターのファイブフォース分析

第6章 経鼻ドラッグデリバリー市場に対するCOVID-19の影響分析

第7章 経鼻ドラッグデリバリー市場の概要

  • 剤形別
  • 容器別
  • システム別
  • 治療用途別
  • エンドユーザー別
  • 地域別

第8章 経鼻ドラッグデリバリーの世界企業シェア分析-主要3~5社

第9章 経鼻ドラッグデリバリー企業と製品プロファイル

  • AFT Pharmaceuticals
  • AptarGroup, Inc.
  • SaNOtize Research & Development Corp.
  • Becton, Dickinson and Company
  • Oyster Point Pharma, Inc.
  • Impel Neuropharma
  • Teleflex Incorporated
  • SipNose
  • Kurve Technology, Inc.
  • Mystic Pharmaceuticals
  • Medica Holdings, LLC
  • 3M Company
  • Neurelis, Inc.
  • PENDOPHARM
  • GlaxoSmithKline
  • Cipla
  • Glenmark Pharmaceuticals
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Intranasal Drug Delivery Market
  • Table 3 Intranasal Drug Delivery Market Analysis in Global (2021-2030)
  • Table 4 Intranasal Drug Delivery Market Analysis in Global by Dosage Form (2021-2030)
  • Table 5 Intranasal Drug Delivery Market Analysis in Global by Container (2021-2030)
  • Table 6 Intranasal Drug Delivery Market Analysis in Global by System (2021-2030)
  • Table 7 Intranasal Drug Delivery Market Analysis in Global by Therapeutic Application (2021-2030)
  • Table 8 Intranasal Drug Delivery Market Analysis in Global by End User (2021-2030)
  • Table 9 Intranasal Drug Delivery Market Analysis in Global by Geography (2021-2030)
  • Table 10 Intranasal Drug Delivery Market Analysis in North America (2021-2030)
  • Table 11 Intranasal Drug Delivery Market Analysis in North America by Dosage Form (2021-2030)
  • Table 12 Intranasal Drug Delivery Market Analysis in North America by Container (2021-2030)
  • Table 13 Intranasal Drug Delivery Market Analysis in North America by System (2021-2030)
  • Table 14 Intranasal Drug Delivery Market Analysis in North America by Therapeutic Application (2021-2030)
  • Table 15 Intranasal Drug Delivery Market Analysis in North America by End User (2021-2030)
  • Table 16 Intranasal Drug Delivery Market Analysis in North America by Country (2021-2030)
  • Table 17 Intranasal Drug Delivery Market Analysis in the US (2021-2030)
  • Table 18 Intranasal Drug Delivery Market Analysis in Canada (2021-2030)
  • Table 19 Intranasal Drug Delivery Market Analysis in Mexico (2021-2030)
  • Table 20 Intranasal Drug Delivery Market Analysis in Europe (2021-2030)
  • Table 21 Intranasal Drug Delivery Market Analysis in Europe by Dosage Form (2021-2030)
  • Table 22 Intranasal Drug Delivery Market Analysis in Europe by Container (2021-2030)
  • Table 23 Intranasal Drug Delivery Market Analysis in Europe by System (2021-2030)
  • Table 24 Intranasal Drug Delivery Market Analysis in Europe by Therapeutic Application (2021-2030)
  • Table 25 Intranasal Drug Delivery Market Analysis in Europe by End User (2021-2030)
  • Table 26 Intranasal Drug Delivery Market Analysis in Europe by Country (2021-2030)
  • Table 27 Intranasal Drug Delivery Market Analysis in France (2021-2030)
  • Table 28 Intranasal Drug Delivery Market Analysis in Germany (2021-2030)
  • Table 29 Intranasal Drug Delivery Market Analysis in UK (2021-2030)
  • Table 30 Intranasal Drug Delivery Market Analysis in Italy (2021-2030)
  • Table 31 Intranasal Drug Delivery Market Analysis in Spain (2021-2030)
  • Table 32 Intranasal Drug Delivery Market Analysis in Russia (2021-2030)
  • Table 33 Intranasal Drug Delivery Market Analysis in Rest of Europe (2021-2030)
  • Table 34 Intranasal Drug Delivery Market Analysis in Asia Pacific (2021-2030)
  • Table 35 Intranasal Drug Delivery Market Analysis in Asia Pacific by Dosage Form (2021-2030)
  • Table 36 Intranasal Drug Delivery Market Analysis in Asia Pacific by Container (2021-2030)
  • Table 37 Intranasal Drug Delivery Market Analysis in Asia Pacific by System (2021-2030)
  • Table 38 Intranasal Drug Delivery Market Analysis in Asia Pacific by Therapeutic Application (2021-2030)
  • Table 39 Intranasal Drug Delivery Market Analysis in Asia Pacific by End User (2021-2030)
  • Table 40 Intranasal Drug Delivery Market Analysis in Asia Pacific by Country (2021-2030)
  • Table 41 Intranasal Drug Delivery Market Analysis in China (2021-2030)
  • Table 42 Intranasal Drug Delivery Market Analysis in Japan (2021-2030)
  • Table 43 Intranasal Drug Delivery Market Analysis in India (2021-2030)
  • Table 44 Intranasal Drug Delivery Market Analysis in Australia (2021-2030)
  • Table 45 Intranasal Drug Delivery Market Analysis in South Korea (2021-2030)
  • Table 46 Intranasal Drug Delivery Market Analysis in Rest of Asia Pacific (2021-2030)
  • Table 47 Intranasal Drug Delivery Market Analysis in Rest of the World (2021-2030)
  • Table 48 Intranasal Drug Delivery Market Analysis in Rest of the World by Dosage Form (2021-2030)
  • Table 49 Intranasal Drug Delivery Market Analysis in Rest of the World by Container (2021-2030)
  • Table 50 Intranasal Drug Delivery Market Analysis in Rest of the World by System (2021-2030)
  • Table 51 Intranasal Drug Delivery Market Analysis in Rest of the World by Therapeutic Application (2021-2030)
  • Table 52 Intranasal Drug Delivery Market Analysis in Rest of the World by End User (2021-2030)
  • Table 53 Intranasal Drug Delivery Market Analysis in Rest of the World by Country (2021-2030)
  • Table 54 Intranasal Drug Delivery Market Analysis in Middle East (2021-2030)
  • Table 55 Intranasal Drug Delivery Market Analysis in Africa (2021-2030)
  • Table 56 Intranasal Drug Delivery Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Intranasal Drug Delivery Market
  • Figure 3 Intranasal Drug Delivery Market Analysis in Global (2021-2030)
  • Figure 4 Intranasal Drug Delivery Market Analysis in Global by Dosage Form (2021-2030)
  • Figure 5 Intranasal Drug Delivery Market Analysis in Global by Container (2021-2030)
  • Figure 6 Intranasal Drug Delivery Market Analysis in Global by System (2021-2030)
  • Figure 7 Intranasal Drug Delivery Market Analysis in Global by Therapeutic Application (2021-2030)
  • Figure 8 Intranasal Drug Delivery Market Analysis in Global by End User (2021-2030)
  • Figure 9 Intranasal Drug Delivery Market Analysis in Global by Geography (2021-2030)
  • Figure 10 Intranasal Drug Delivery Market Analysis in North America (2021-2030)
  • Figure 11 Intranasal Drug Delivery Market Analysis in North America by Dosage Form (2021-2030)
  • Figure 12 Intranasal Drug Delivery Market Analysis in North America by Container (2021-2030)
  • Figure 13 Intranasal Drug Delivery Market Analysis in North America by System (2021-2030)
  • Figure 14 Intranasal Drug Delivery Market Analysis in North America by Therapeutic Application (2021-2030)
  • Figure 15 Intranasal Drug Delivery Market Analysis in North America by End User (2021-2030)
  • Figure 16 Intranasal Drug Delivery Market Analysis in North America by Country (2021-2030)
  • Figure 17 Intranasal Drug Delivery Market Analysis in the US (2021-2030)
  • Figure 18 Intranasal Drug Delivery Market Analysis in Canada (2021-2030)
  • Figure 19 Intranasal Drug Delivery Market Analysis in Mexico (2021-2030)
  • Figure 20 Intranasal Drug Delivery Market Analysis in Europe (2021-2030)
  • Figure 21 Intranasal Drug Delivery Market Analysis in Europe by Dosage Form (2021-2030)
  • Figure 22 Intranasal Drug Delivery Market Analysis in Europe by Container (2021-2030)
  • Figure 23 Intranasal Drug Delivery Market Analysis in Europe by System (2021-2030)
  • Figure 24 Intranasal Drug Delivery Market Analysis in Europe by Therapeutic Application (2021-2030)
  • Figure 25 Intranasal Drug Delivery Market Analysis in Europe by End User (2021-2030)
  • Figure 26 Intranasal Drug Delivery Market Analysis in Europe by Country (2021-2030)
  • Figure 27 Intranasal Drug Delivery Market Analysis in France (2021-2030)
  • Figure 28 Intranasal Drug Delivery Market Analysis in Germany (2021-2030)
  • Figure 29 Intranasal Drug Delivery Market Analysis in UK (2021-2030)
  • Figure 30 Intranasal Drug Delivery Market Analysis in Italy (2021-2030)
  • Figure 31 Intranasal Drug Delivery Market Analysis in Spain (2021-2030)
  • Figure 32 Intranasal Drug Delivery Market Analysis in Russia (2021-2030)
  • Figure 33 Intranasal Drug Delivery Market Analysis in Rest of Europe (2021-2030)
  • Figure 34 Intranasal Drug Delivery Market Analysis in Asia Pacific (2021-2030)
  • Figure 35 Intranasal Drug Delivery Market Analysis in Asia Pacific by Dosage Form (2021-2030)
  • Figure 36 Intranasal Drug Delivery Market Analysis in Asia Pacific by Container (2021-2030)
  • Figure 37 Intranasal Drug Delivery Market Analysis in Asia Pacific by System (2021-2030)
  • Figure 38 Intranasal Drug Delivery Market Analysis in Asia Pacific by Therapeutic Application (2021-2030)
  • Figure 39 Intranasal Drug Delivery Market Analysis in Asia Pacific by End User (2021-2030)
  • Figure 40 Intranasal Drug Delivery Market Analysis in Asia Pacific by Country (2021-2030)
  • Figure 41 Intranasal Drug Delivery Market Analysis in China (2021-2030)
  • Figure 42 Intranasal Drug Delivery Market Analysis in Japan (2021-2030)
  • Figure 43 Intranasal Drug Delivery Market Analysis in India (2021-2030)
  • Figure 44 Intranasal Drug Delivery Market Analysis in Australia (2021-2030)
  • Figure 45 Intranasal Drug Delivery Market Analysis in South Korea (2021-2030)
  • Figure 46 Intranasal Drug Delivery Market Analysis in Rest of Asia Pacific (2021-2030)
  • Figure 47 Intranasal Drug Delivery Market Analysis in Rest of the World (2021-2030)
  • Figure 48 Intranasal Drug Delivery Market Analysis in Rest of the World by Dosage Form (2021-2030)
  • Figure 49 Intranasal Drug Delivery Market Analysis in Rest of the World by Container (2021-2030)
  • Figure 50 Intranasal Drug Delivery Market Analysis in Rest of the World by System (2021-2030)
  • Figure 51 Intranasal Drug Delivery Market Analysis in Rest of the World by Therapeutic Application (2021-2030)
  • Figure 52 Intranasal Drug Delivery Market Analysis in Rest of the World by End User (2021-2030)
  • Figure 53 Intranasal Drug Delivery Market Analysis in Rest of the World by Country (2021-2030)
  • Figure 54 Intranasal Drug Delivery Market Analysis in Middle East (2021-2030)
  • Figure 55 Intranasal Drug Delivery Market Analysis in Africa (2021-2030)
  • Figure 56 Intranasal Drug Delivery Market Analysis in South America (2021-2030)
  • Figure 57 Market Drivers
  • Figure 58 Market Barriers
  • Figure 59 Market Opportunities
  • Figure 60 PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0492

Intranasal Drug Delivery Market By Dosage Form (Spray, Drops And Liquids, Gels, Powders), By Container (Pressurized, Non-Pressurized), By System (Multi-Dose Systems, Bi-Dose Systems, Unit-Dose Systems), By Therapeutic Application (Rhinitis, Sinusitis, Vaccination, Others), By End-User (Hospitals, Home Care Settings), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising burden of various respiratory disorders and extended application of intranasal drugs in various conditions

Global Intranasal Drug Delivery Market was valued at USD 46.00 billion in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 66.33 billion by 2030. The Intranasal Drug Delivery market is expected to witness growth owing to the rising burden of various respiratory disorders such as rhinitis and sinusitis among the worldwide population, increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy, the extended application of intranasal drugs in various conditions, rise in product approval and launches.

Intranasal Drug Delivery Market Dynamics:

Owing to the growing burden of respiratory diseases across the globe, the Intranasal Drug Delivery market has been rising significantly.

Rhinosinusitis is a common condition associated with the inflammation of the nasal cavity along with paranasal sinuses. According to the World Allergy Organization 2022 report, the worldwide prevalence of chronic rhinosinusitis (CRS) ranges from about 8% in China, 8.4% in Korea, 11% in Europe, and 12% in the United States respectively.

Also, according to the reports of the International Rhinologic Society 2020, the one-year prevalence of acute rhinosinusitis which is usually the consequence of viral common cold is 6-15% whereas CRS affects an estimated 5-12% of the general population.

In addition, according to Allergy UK, a British medical charity dedicated to helping adults and children with their allergies, around 49% of people reported suffering from allergic rhinitis in the UK in the year 2020.

Furthermore, as per the data provided by the Australian Government in the year 2020, approximately 1 in 5 Australians or more than 4.6 million people in Australia had allergic rhinitis in the year 2017-2018.

Report Metrics

Details

Study Period

2021 to 2030

Base Year

2022

Forecast Period

2024 to 2030

CAGR

6.29%

Market Size

USD 66.33 billion by 2030

Key Companies

AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, and others

Thus, the rising prevalence of respiratory disorders such as allergic rhinitis, rhinosinusitis, and others are key factors contributing to the Intranasal Drug Delivery market growth during the forecasted period.

COVID-19 has caused significant disruption to business and economic activity globally and is expected to have impacted the intranasal drug delivery market. This is due to factors including lockdown restriction, supply chain disruption due to logistical restrictions, among others. However, the pandemic has also allowed the Intranasal Drug Delivery market as various manufacturers are focused on developing intranasal vaccines for the COVID-19 infection, for instance, Canadian biotech firm SaNOtize Research & Development Corp is one of them.

However, certain factors like complications and limitations associated with the intranasal drug administration and product recalls may restrict the growth of the Global Intranasal Drug Delivery Market.

Intranasal Drug Delivery Market Segment Analysis:

Intranasal Drug Delivery Market By Dosage Form (Spray, Drops and Liquids, Gels, Powders), By Container (Pressurized, Non-Pressurized), By System (Multi-dose Systems, Bi-dose Systems, Unit-dose Systems), By Therapeutic Application (Rhinitis, Sinusitis, Vaccination, Others), By End-User (Hospitals, Home Care Settings), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In Intranasal Drug Delivery market Dosage Form segment, the Sprays market segment will hold the major share of the Global Intranasal Drug Delivery market. This is owing to the wide availability of intranasal sprays to deliver medications locally in the nasal cavities or systemically for various applications such as congested nose, migraine, and others.

Furthermore, rising COVID-19 cases across the globe and an increase in research and development activities for developing intranasal sprays for the infection is also a factor responsible for augmenting the market for intranasal sprays in the forthcoming years.

In addition, the expansion of intranasal spray to treat a variety of different diseases and their approval is also expected to surge the market for intranasal drug delivery in the upcoming years.

Hence, all the above-mentioned factors are expected to bolster the segmental growth in the forthcoming years.

North America is expected to dominate the overall Global Intranasal Drug Delivery Market:

North America is expected to dominate the overall Intranasal Drug Delivery market during the forecast period. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of a well-established reimbursement policy and recent product approvals in the region is projected to augment the intranasal drug delivery regional market.

For instance, as per the 2022 data of the Centre for Disease Control and Prevention, in the US, there are approximately 28.9 million adult persons diagnosed with sinusitis.

Further, in North America and at the global level the United States represents the largest market worldwide supported by developed healthcare infrastructure and strong adoption of technologically advanced products owing to the rise in healthcare expenditure by the government and increase prevalence and incidence of respiratory disease.

In addition, the presence of key market players such as Becton, Dickinson, and Company, Aptar Group., among others, and their strategic business activities for market expansion is also expected to bolster the intranasal drug delivery market in the country.

For instance, on March 18, 2019, Aptar Pharma, a leading drug delivery systems provider received FDA approval for its Bidose nasal spray device as a breakthrough therapy in the field of depression. This marks the first FDA approval and the US launch of a prescription drug using Aptar Pharma's patented Bidose nasal spray delivery system.

Hence, the interplay of all the above-mentioned factors is likely to drive the market for intranasal drug delivery market in the country during the forecasted period.

Intranasal Drug Delivery Market Key Players:

Some of the key market players operating in the Global Intranasal Drug Delivery Market include AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, Inc., Mystic Pharmaceuticals, Medica Holdings, LLC, 3M Company, Neurelis, Inc., PENDOPHARM, GlaxoSmithKline, Cipla, Glenmark Pharmaceuticals, Novartis AG, AstraZeneca, Johnson & Johnson, and others.

Recent Developmental Activities in the Intranasal Drug Delivery Market:

In October 2022, Oyster Point Pharma's dry-eye treatment, Tyrvaya (varenicline), won FDA approval as the first nasal spray in the U.S. to treat the chronic condition of dry eye.

On August 02, 2022, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, and Canadian biotech firm SaNOtize Research & Development Corp. inked an exclusive long term strategic partnership to manufacture, market, and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, and other countries.

Key Takeaways from the Intranasal Drug Delivery Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Intranasal Drug Delivery market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Intranasal Drug Delivery Market.

Various opportunities are available for the other competitor in the Intranasal Drug Delivery Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Intranasal Drug Delivery market growth in the coming future?

Target Audience who can be benefited from this Intranasal Drug Delivery Market Report Study

Intranasal Drug Delivery providers

Research organizations and consulting companies

Intranasal Drug Delivery related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Intranasal Drug Delivery

Various End-users want to know more about the Intranasal Drug Delivery Market and the latest technological developments in the Intranasal Drug Delivery market.

Frequently Asked Questions for Intranasal Drug Delivery Market:

1. What are Intranasal Drug Delivery Devices?

Intranasal drug delivery devices are next-generation post-surgery devices, offering advantages for enhancing tissue recovery through the release of loaded therapeutic drugs locally in a controlled manner over the required time frame during post-operative healing.

2. What is the market for Global Intranasal Drug Delivery?

Global Intranasal Drug Delivery Market was valued at USD 46.00 billion in 2023, growing at a CAGR of 6.29% during the forecast period from 2024 to 2030, in order to reach USD 66.33 billion by 2030.

3. What are the drivers for Global Intranasal Drug Delivery?

The major drivers driving the demand for Intranasal Drug Delivery are the rising burden of various respiratory disorders such as rhinitis and sinusitis among the worldwide population, increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy, the extended application of intranasal drugs in various conditions, rise in product approval and launches.

4. What are the key players operating in Global Intranasal Drug Delivery?

Some of the key market players operating in the Intranasal Drug Delivery market include AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, Inc., Mystic Pharmaceuticals, Medica Holdings, LLC, 3M Company, Neurelis, Inc., PENDOPHARM, GlaxoSmithKline, Cipla, Glenmark Pharmaceuticals, Novartis AG, AstraZeneca, Johnson & Johnson, and others.

5. Which regions has the highest share in the Intranasal Drug Delivery market?

North America is expected to dominate the overall global Intranasal Drug Delivery market during the forecast period from 2024 to 2030. This domination is owing to the increasing prevalence of the target population in the region. Moreover, the presence of a well-established reimbursement policy and recent product approvals in the region is projected to augment the intranasal drug delivery regional market.

Table of Contents

1.Intranasal Drug Delivery Market Report Introduction

2.Intranasal Drug Delivery Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Intranasal Drug Delivery Market Key factors analysis

  • 4.1 Intranasal Drug Delivery Market Drivers
    • 4.1.1 Rising Burden of various Respiratory Disorders among the Worldwide Population
    • 4.1.2 Increasing Patient Preference for Nasal Drug Delivery
    • 4.1.3 Extended Application of Intranasal Drugs in Various Conditions
    • 4.1.4 The rise in Product Approval and Launches
  • 4.2 Intranasal Drug Delivery Restraints and Challenges
    • 4.2.1 Complications and Limitations associated with the Intranasal Drug Administration
    • 4.2.2 Product Recalls
  • 4.3 Intranasal Drug Delivery Opportunities
    • 4.3.1 Growth Opportunities in Low-Income Regions
    • 4.3.2 Growth Opportunities due to Strategic Business Activities by Companies for Market Expansion

5. Intranasal Drug Delivery Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Intranasal Drug Delivery Market

7. Intranasal Drug Delivery Market layout

  • 7.1 By Dosage Form
    • 7.1.1 Spray
    • 7.1.2 Drops and Liquids
    • 7.1.3 Gels
    • 7.1.4 Powders
  • 7.2 By Container
    • 7.2.1 Pressurized
    • 7.2.2 Non-Pressurized
  • 7.3 By System
    • 7.3.1 Multi-dose Systems
    • 7.3.2 Bi-dose Systems
    • 7.3.3 Unit-dose Systems
  • 7.4 By Therapeutic Application
    • 7.4.1 Rhinitis
    • 7.4.2 Sinusitis
    • 7.4.3 Vaccination
    • 7.4.4 Others
  • 7.5 By End User
    • 7.5.1 Hospitals
    • 7.5.2 Home Care Settings
  • 7.6 By Geography
    • 7.6.1 North America
      • 7.6.1.1 North America Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.1.2 North America Intranasal Drug Delivery Market, by Container
      • 7.6.1.3 North America Intranasal Drug Delivery Market, by System
      • 7.6.1.4 North America Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.1.5 North America Intranasal Drug Delivery Market, by End User
      • 7.6.1.6 North America Intranasal Drug Delivery Market, by Country
      • 7.6.1.6.1 United States
      • 7.6.1.6.2 Canada
      • 7.6.1.6.3 Mexico
    • 7.6.2 Europe
      • 7.6.2.1 Europe Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.2.2 Europe Intranasal Drug Delivery Market, by Container
      • 7.6.2.3 Europe Intranasal Drug Delivery Market, by System
      • 7.6.2.4 Europe Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.2.5 Europe Intranasal Drug Delivery Market, by End User
      • 7.6.2.6 Europe Intranasal Drug Delivery Market, by Country
      • 7.6.2.6.1 France
      • 7.6.2.6.2 Germany
      • 7.6.2.6.3 United Kingdom
      • 7.6.2.6.4 Italy
      • 7.6.2.6.5 Spain
      • 7.6.2.6.6 Russia
      • 7.6.2.6.7 Rest of Europe
    • 7.6.3 Asia-Pacific
      • 7.6.3.1 Asia-Pacific Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.3.2 Asia-Pacific Intranasal Drug Delivery Market, by Container
      • 7.6.3.3 Asia-Pacific Intranasal Drug Delivery Market, by System
      • 7.6.3.4 Asia-Pacific Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.3.5 Asia-Pacific Intranasal Drug Delivery Market, by End User
      • 7.6.3.6 Asia-Pacific Intranasal Drug Delivery Market, by Country
      • 7.6.3.6.1 China
      • 7.6.3.6.2 Japan
      • 7.6.3.6.3 India
      • 7.6.3.6.4 Australia
      • 7.6.3.6.5 South Korea
      • 7.6.3.6.6 Rest of Asia Pacific
    • 7.6.4 Rest of the World (RoW)
      • 7.6.4.1 RoW Intranasal Drug Delivery Market, by Dosage Form
      • 7.6.4.2 RoW Intranasal Drug Delivery Market, by Container
      • 7.6.4.3 RoW Intranasal Drug Delivery Market, by System
      • 7.6.4.4 RoW Intranasal Drug Delivery Market, by Therapeutic Application
      • 7.6.4.5 RoW Intranasal Drug Delivery Market, by End User
      • 7.6.4.6 RoW Intranasal Drug Delivery Market, by Region
      • 7.6.4.6.1 Middle East
      • 7.6.4.6.2 Africa
      • 7.6.4.6.3 South America

8. Intranasal Drug Delivery Global Company Share Analysis - Key 3-5 Companies

9. Intranasal Drug Delivery Company and Product Profiles

  • 9.1 AFT Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 AptarGroup, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 SaNOtize Research & Development Corp.
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Becton, Dickinson and Company
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Oyster Point Pharma, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Impel Neuropharma
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Teleflex Incorporated
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 SipNose
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Kurve Technology, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Mystic Pharmaceuticals
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 Medica Holdings, LLC
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 3M Company
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Neurelis, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 PENDOPHARM
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 GlaxoSmithKline
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 Cipla
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Glenmark Pharmaceuticals
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Novartis AG
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 AstraZeneca
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 Johnson & Johnson
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. PROJECT APPROACH

12. About DelveInsight

13. Disclaimer & Contact Us